Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 428 entries
Sorted by: Best Match Show Resources per page
Almonds vs complex carbohydrates in a weight reduction program

program design

Sabate JM.
GSID: aXmkeQBe74YJ
MA Wien, JM Sabate, DN Ikle, SE Cole… - International journal of …, 2003 - nature.com

… and metabolic parameters during a 24-week weight reduction program in overweight and obese adults. Both nutritional interventions were … The difference in weight loss was unexpected, given the study design featuring a matched prescribed total calorie intake and...

Cite
Wien, M. A., Sabate, J. M., Ikle, D. N., Cole, S. E., & Kandeel, F. R. (2003). Almonds vs complex carbohydrates in a weight reduction program. International journal of obesity, 27(11), 1365-1372.
Wien, M. A., et al. "Almonds vs complex carbohydrates in a weight reduction program." International journal of obesity 27.11 (2003): 1365-1372.
Copy Download .nbib Format: MLA
Conservative management of aortic root rupture complicated with cardiac tamponade following transcatheter aortic valve implantation.

World journal of cardiology

Vannini L, Andrea R, Sabaté M.
PMID: 28515859
World J Cardiol. 2017 Apr 26;9(4):391-395. doi: 10.4330/wjc.v9.i4.391.

Aortic root rupture and cardiac tamponade during transcatheter aortic valve implantation is a frightening complication with high mortality rate. A conservative management of this complication could represent an initial strategy, especially in high-risk patients, to avoid emergent cardiac surgery....

Cite
Vannini L, Andrea R, Sabaté M. Conservative management of aortic root rupture complicated with cardiac tamponade following transcatheter aortic valve implantation. World J Cardiol. 2017;9(4):391-395doi: 10.4330/wjc.v9.i4.391.
Vannini, L., Andrea, R., & Sabaté, M. (2017). Conservative management of aortic root rupture complicated with cardiac tamponade following transcatheter aortic valve implantation. World journal of cardiology, 9(4), 391-395. https://doi.org/10.4330/wjc.v9.i4.391
Vannini, Luca, et al. "Conservative management of aortic root rupture complicated with cardiac tamponade following transcatheter aortic valve implantation." World journal of cardiology vol. 9,4 (2017): 391-395. doi: https://doi.org/10.4330/wjc.v9.i4.391
Vannini L, Andrea R, Sabaté M. Conservative management of aortic root rupture complicated with cardiac tamponade following transcatheter aortic valve implantation. World J Cardiol. 2017 Apr 26;9(4):391-395. doi: 10.4330/wjc.v9.i4.391. PMID: 28515859; PMCID: PMC5411975.
Copy Download .nbib Format: NLM
Targeted therapies and immunotherapy in non-small-cell lung cancer.

Ecancermedicalscience

Cortinovis D, Abbate M, Bidoli P, Capici S, Canova S.
PMID: 27433281
Ecancermedicalscience. 2016 Jun 23;10:648. doi: 10.3332/ecancer.2016.648. eCollection 2016.

Non-small-cell lung cancer is still considered a difficult disease to manage because of its aggressiveness and resistance to common therapies. Chemotherapy remains the gold standard in nearly 80% of lung cancers, but clinical outcomes are discouraging, and the impact...

Cite
Cortinovis D, Abbate M, Bidoli P, et al. Targeted therapies and immunotherapy in non-small-cell lung cancer. Ecancermedicalscience. 2016;10:648doi: 10.3332/ecancer.2016.648.
Cortinovis, D., Abbate, M., Bidoli, P., Capici, S., & Canova, S. (2016). Targeted therapies and immunotherapy in non-small-cell lung cancer. Ecancermedicalscience, 10648. https://doi.org/10.3332/ecancer.2016.648
Cortinovis, D, et al. "Targeted therapies and immunotherapy in non-small-cell lung cancer." Ecancermedicalscience vol. 10 (2016): 648. doi: https://doi.org/10.3332/ecancer.2016.648
Cortinovis D, Abbate M, Bidoli P, Capici S, Canova S. Targeted therapies and immunotherapy in non-small-cell lung cancer. Ecancermedicalscience. 2016 Jun 23;10:648. doi: 10.3332/ecancer.2016.648. eCollection 2016. PMID: 27433281; PMCID: PMC4929979.
Copy Download .nbib Format: NLM
Phase I trial to evaluate the tumor and normal tissue uptake, radiation dosimetry and safety of (111)In-DTPA-human epidermal growth factor in patients with metastatic EGFR-positive breast cancer.

American journal of nuclear medicine and molecular imaging

Vallis KA, Reilly RM, Scollard D, Merante P, Brade A, Velauthapillai S, Caldwell C, Chan I, Freeman M, Lockwood G, Miller NA, Cornelissen B, Petronis J, Sabate K.
PMID: 24753984
Am J Nucl Med Mol Imaging. 2014 Mar 20;4(2):181-92. eCollection 2014.

The safety, pharmacokinetics, biodistribution and radiation dosimetry of (111)In-DTPA-hEGF, an Auger electron-emitting radiopharmaceutical, were evaluated in a first-in-human trial. Dose escalation was performed in patients with EGFR-positive metastatic breast cancer who had received ≥2 prior courses of systemic treatment....

Cite
Vallis KA, Reilly RM, Scollard D, et al. Phase I trial to evaluate the tumor and normal tissue uptake, radiation dosimetry and safety of (111)In-DTPA-human epidermal growth factor in patients with metastatic EGFR-positive breast cancer. Am J Nucl Med Mol Imaging. 2014;4(2):181-92
Vallis, K. A., Reilly, R. M., Scollard, D., Merante, P., Brade, A., Velauthapillai, S., Caldwell, C., Chan, I., Freeman, M., Lockwood, G., Miller, N. A., Cornelissen, B., Petronis, J., & Sabate, K. (2014). Phase I trial to evaluate the tumor and normal tissue uptake, radiation dosimetry and safety of (111)In-DTPA-human epidermal growth factor in patients with metastatic EGFR-positive breast cancer. American journal of nuclear medicine and molecular imaging, 4(2), 181-92.
Vallis, Katherine A, et al. "Phase I trial to evaluate the tumor and normal tissue uptake, radiation dosimetry and safety of (111)In-DTPA-human epidermal growth factor in patients with metastatic EGFR-positive breast cancer." American journal of nuclear medicine and molecular imaging vol. 4,2 (2014): 181-92.
Vallis KA, Reilly RM, Scollard D, Merante P, Brade A, Velauthapillai S, Caldwell C, Chan I, Freeman M, Lockwood G, Miller NA, Cornelissen B, Petronis J, Sabate K. Phase I trial to evaluate the tumor and normal tissue uptake, radiation dosimetry and safety of (111)In-DTPA-human epidermal growth factor in patients with metastatic EGFR-positive breast cancer. Am J Nucl Med Mol Imaging. 2014 Mar 20;4(2):181-92. eCollection 2014. PMID: 24753984; PMCID: PMC3992211.
Copy Download .nbib Format: NLM
Molecular recognition of aliphatic diamines by 3,3'-di(trifluoroacetyl)-1,1'-bi-2-naphthol.

The Journal of organic chemistry

Yu S, Plunkett W, Kim M, Wu E, Sabat M, Pu L.
PMID: 24283254
J Org Chem. 2013 Dec 20;78(24):12671-80. doi: 10.1021/jo402277p. Epub 2013 Dec 06.

The fluorescent responses of 3,3'-di(trifluoroacetyl)-1,1'-bi-2-naphthol toward a variety of amines have been studied. It was found that the aliphatic primary 1,2- and 1,5-diamines can greatly enhance the fluorescence of this compound, but under the same conditions, primary, secondary, and...

Cite
Yu S, Plunkett W, Kim M, et al. Molecular recognition of aliphatic diamines by 3,3'-di(trifluoroacetyl)-1,1'-bi-2-naphthol. J Org Chem. 2013;78(24):12671-80doi: 10.1021/jo402277p.
Yu, S., Plunkett, W., Kim, M., Wu, E., Sabat, M., & Pu, L. (2013). Molecular recognition of aliphatic diamines by 3,3'-di(trifluoroacetyl)-1,1'-bi-2-naphthol. The Journal of organic chemistry, 78(24), 12671-80. https://doi.org/10.1021/jo402277p
Yu, Shanshan, et al. "Molecular recognition of aliphatic diamines by 3,3'-di(trifluoroacetyl)-1,1'-bi-2-naphthol." The Journal of organic chemistry vol. 78,24 (2013): 12671-80. doi: https://doi.org/10.1021/jo402277p
Yu S, Plunkett W, Kim M, Wu E, Sabat M, Pu L. Molecular recognition of aliphatic diamines by 3,3'-di(trifluoroacetyl)-1,1'-bi-2-naphthol. J Org Chem. 2013 Dec 20;78(24):12671-80. doi: 10.1021/jo402277p. Epub 2013 Dec 06. PMID: 24283254.
Copy Download .nbib Format: NLM
HER2 status in advanced gastric carcinoma: A retrospective multicentric analysis from Sicily.

Oncology letters

Ieni A, Barresi V, Giuffrè G, Caruso RA, Lanzafame S, Villari L, Salomone E, Roz E, Cabibi D, Franco V, Certo G, Labate A, Nagar C, Magliolo E, Broggi B, Fazzari C, Italia F, Tuccari G.
PMID: 24260051
Oncol Lett. 2013 Dec;6(6):1591-1594. doi: 10.3892/ol.2013.1611. Epub 2013 Oct 10.

According to the ToGA trial, HER2 has been shown to be predictive for the success of treatment with trastuzumab in advanced gastric cancer (AGC). A number of studies have analyzed HER-2/neu overexpression in gastric carcinoma and identified the rate...

Cite
Ieni A, Barresi V, Giuffrè G, et al. HER2 status in advanced gastric carcinoma: A retrospective multicentric analysis from Sicily. Oncol Lett. 2013;6(6):1591-1594doi: 10.3892/ol.2013.1611.
Ieni, A., Barresi, V., Giuffrè, G., Caruso, R. A., Lanzafame, S., Villari, L., Salomone, E., Roz, E., Cabibi, D., Franco, V., Certo, G., Labate, A., Nagar, C., Magliolo, E., Broggi, B., Fazzari, C., Italia, F., & Tuccari, G. (2013). HER2 status in advanced gastric carcinoma: A retrospective multicentric analysis from Sicily. Oncology letters, 6(6), 1591-1594. https://doi.org/10.3892/ol.2013.1611
Ieni, A, et al. "HER2 status in advanced gastric carcinoma: A retrospective multicentric analysis from Sicily." Oncology letters vol. 6,6 (2013): 1591-1594. doi: https://doi.org/10.3892/ol.2013.1611
Ieni A, Barresi V, Giuffrè G, Caruso RA, Lanzafame S, Villari L, Salomone E, Roz E, Cabibi D, Franco V, Certo G, Labate A, Nagar C, Magliolo E, Broggi B, Fazzari C, Italia F, Tuccari G. HER2 status in advanced gastric carcinoma: A retrospective multicentric analysis from Sicily. Oncol Lett. 2013 Dec;6(6):1591-1594. doi: 10.3892/ol.2013.1611. Epub 2013 Oct 10. PMID: 24260051; PMCID: PMC3833944.
Copy Download .nbib Format: NLM
C-H activation of pyrazolyl ligands by Ru(II).

Inorganic chemistry

Joslin EE, Quillian B, Gunnoe TB, Cundari TR, Sabat M, Myers WH.
PMID: 24866703
Inorg Chem. 2014 Jun 16;53(12):6270-9. doi: 10.1021/ic500811n. Epub 2014 May 27.

Previously, hydridotris(pyrazolyl)borate (Tp) Ru(II) alkyl and aryl complexes of the type TpRu(L)(NCMe)R (R = methyl or aryl; L = charge-neutral two-electron donating ligand) were demonstrated to activate aromatic C-H bonds. To determine the impact of replacing the anionic Tp...

Cite
Joslin EE, Quillian B, Gunnoe TB, et al. C-H activation of pyrazolyl ligands by Ru(II). Inorg Chem. 2014;53(12):6270-9doi: 10.1021/ic500811n.
Joslin, E. E., Quillian, B., Gunnoe, T. B., Cundari, T. R., Sabat, M., & Myers, W. H. (2014). C-H activation of pyrazolyl ligands by Ru(II). Inorganic chemistry, 53(12), 6270-9. https://doi.org/10.1021/ic500811n
Joslin, Evan E, et al. "C-H activation of pyrazolyl ligands by Ru(II)." Inorganic chemistry vol. 53,12 (2014): 6270-9. doi: https://doi.org/10.1021/ic500811n
Joslin EE, Quillian B, Gunnoe TB, Cundari TR, Sabat M, Myers WH. C-H activation of pyrazolyl ligands by Ru(II). Inorg Chem. 2014 Jun 16;53(12):6270-9. doi: 10.1021/ic500811n. Epub 2014 May 27. PMID: 24866703.
Copy Download .nbib Format: NLM
A possible case of natalizumab-dependent suicide attempt: A brief review about drugs and suicide.

Journal of pharmacology & pharmacotherapeutics

Mumoli L, Ciriaco M, Gambardella A, Bombardiere GN, Valentino P, Palleria C, Labate A, Russo E.
PMID: 24347991
J Pharmacol Pharmacother. 2013 Dec;4:S90-3. doi: 10.4103/0976-500X.120974.

β-Interferon therapy is known to be a potential trigger of suicidal behavior, but this effect has not been previously reported for other multiple sclerosis (MS) treatments, such as, natalizumab. Here we report the case history of a 32-year-old woman...

Cite
Mumoli L, Ciriaco M, Gambardella A, et al. A possible case of natalizumab-dependent suicide attempt: A brief review about drugs and suicide. J Pharmacol Pharmacother. 2013;4:S90-3doi: 10.4103/0976-500X.120974.
Mumoli, L., Ciriaco, M., Gambardella, A., Bombardiere, G. N., Valentino, P., Palleria, C., Labate, A., & Russo, E. (2013). A possible case of natalizumab-dependent suicide attempt: A brief review about drugs and suicide. Journal of pharmacology & pharmacotherapeutics, 4S90-3. https://doi.org/10.4103/0976-500X.120974
Mumoli, Laura, et al. "A possible case of natalizumab-dependent suicide attempt: A brief review about drugs and suicide." Journal of pharmacology & pharmacotherapeutics vol. 4 (2013): S90-3. doi: https://doi.org/10.4103/0976-500X.120974
Mumoli L, Ciriaco M, Gambardella A, Bombardiere GN, Valentino P, Palleria C, Labate A, Russo E. A possible case of natalizumab-dependent suicide attempt: A brief review about drugs and suicide. J Pharmacol Pharmacother. 2013 Dec;4:S90-3. doi: 10.4103/0976-500X.120974. PMID: 24347991; PMCID: PMC3853678.
Copy Download .nbib Format: NLM
How obesity modifies tendons (implications for athletic activities).

Muscles, ligaments and tendons journal

Abate M.
PMID: 25489546
Muscles Ligaments Tendons J. 2014 Nov 17;4(3):298-302. eCollection 2014 Jul.

BACKGROUND: obesity is a well recognized risk factor for dysmetabolic and cardiovascular diseases, but can also be associated to musculo-skeletal disorders.METHODS: a search of English-language articles was performed using the key search terms "obesity" or "body mass index" combined...

Cite
Abate M. How obesity modifies tendons (implications for athletic activities). Muscles Ligaments Tendons J. 2014;4(3):298-302
Abate, M. (2014). How obesity modifies tendons (implications for athletic activities). Muscles, ligaments and tendons journal, 4(3), 298-302.
Abate, Michele. "How obesity modifies tendons (implications for athletic activities)." Muscles, ligaments and tendons journal vol. 4,3 (2014): 298-302.
Abate M. How obesity modifies tendons (implications for athletic activities). Muscles Ligaments Tendons J. 2014 Nov 17;4(3):298-302. eCollection 2014 Jul. PMID: 25489546; PMCID: PMC4241419.
Copy Download .nbib Format: NLM
Unusual Neuroimaging Findings in Two Families with Giant Axonal Neuropathy.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques

Jain P, Sharma S, Kamate M, Hattiholi V, Patra B, Mahadevan A, Aneja S.
PMID: 26693541
Can J Neurol Sci. 2014 Nov;41(6):777-9. doi: 10.1017/cjn.2014.102.

No abstract available.

Cite
Jain P, Sharma S, Kamate M, et al. Unusual Neuroimaging Findings in Two Families with Giant Axonal Neuropathy. Can J Neurol Sci. 2014;41(6):777-9doi: 10.1017/cjn.2014.102.
Jain, P., Sharma, S., Kamate, M., Hattiholi, V., Patra, B., Mahadevan, A., & Aneja, S. (2014). Unusual Neuroimaging Findings in Two Families with Giant Axonal Neuropathy. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 41(6), 777-9. https://doi.org/10.1017/cjn.2014.102
Jain, Puneet, et al. "Unusual Neuroimaging Findings in Two Families with Giant Axonal Neuropathy." The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques vol. 41,6 (2014): 777-9. doi: https://doi.org/10.1017/cjn.2014.102
Jain P, Sharma S, Kamate M, Hattiholi V, Patra B, Mahadevan A, Aneja S. Unusual Neuroimaging Findings in Two Families with Giant Axonal Neuropathy. Can J Neurol Sci. 2014 Nov;41(6):777-9. doi: 10.1017/cjn.2014.102. PMID: 26693541.
Copy Download .nbib Format: NLM
Profile of brivaracetam and its potential in the treatment of epilepsy.

Neuropsychiatric disease and treatment

Ferlazzo E, Russo E, Mumoli L, Sueri C, Gasparini S, Palleria C, Labate A, Gambardella A, De Sarro G, Aguglia U.
PMID: 26664121
Neuropsychiatr Dis Treat. 2015 Nov 30;11:2967-73. doi: 10.2147/NDT.S60849. eCollection 2015.

Brivaracetam (BRV) (UCB 34714) is currently under review by the US Food and Drug Administration and European Medicines Agency for approval as an add-on treatment for adult patients with partial seizures. Similar to levetiracetam (LEV), BRV acts as a...

Cite
Ferlazzo E, Russo E, Mumoli L, et al. Profile of brivaracetam and its potential in the treatment of epilepsy. Neuropsychiatr Dis Treat. 2015;11:2967-73doi: 10.2147/NDT.S60849.
Ferlazzo, E., Russo, E., Mumoli, L., Sueri, C., Gasparini, S., Palleria, C., Labate, A., Gambardella, A., De Sarro, G., & Aguglia, U. (2015). Profile of brivaracetam and its potential in the treatment of epilepsy. Neuropsychiatric disease and treatment, 112967-73. https://doi.org/10.2147/NDT.S60849
Ferlazzo, Edoardo, et al. "Profile of brivaracetam and its potential in the treatment of epilepsy." Neuropsychiatric disease and treatment vol. 11 (2015): 2967-73. doi: https://doi.org/10.2147/NDT.S60849
Ferlazzo E, Russo E, Mumoli L, Sueri C, Gasparini S, Palleria C, Labate A, Gambardella A, De Sarro G, Aguglia U. Profile of brivaracetam and its potential in the treatment of epilepsy. Neuropsychiatr Dis Treat. 2015 Nov 30;11:2967-73. doi: 10.2147/NDT.S60849. eCollection 2015. PMID: 26664121; PMCID: PMC4670022.
Copy Download .nbib Format: NLM
Platelet Rich Plasma Therapy in Non-insertional Achilles Tendinopathy: The Efficacy is Reduced in 60-years Old People Compared to Young and Middle-Age Individuals.

Frontiers in aging neuroscience

Salini V, Vanni D, Pantalone A, Abate M.
PMID: 26696880
Front Aging Neurosci. 2015 Dec 10;7:228. doi: 10.3389/fnagi.2015.00228. eCollection 2015.

BACKGROUND: Platelet Rich Plasma (PRP) has shown positive and long-lasting effects in patients with tendinopathies. However, information about age-related differences in the clinical outcome is limited. Aim of this retrospective study was to compare the efficacy of PRP therapy...

Cite
Salini V, Vanni D, Pantalone A, et al. Platelet Rich Plasma Therapy in Non-insertional Achilles Tendinopathy: The Efficacy is Reduced in 60-years Old People Compared to Young and Middle-Age Individuals. Front Aging Neurosci. 2015;7:228doi: 10.3389/fnagi.2015.00228.
Salini, V., Vanni, D., Pantalone, A., & Abate, M. (2015). Platelet Rich Plasma Therapy in Non-insertional Achilles Tendinopathy: The Efficacy is Reduced in 60-years Old People Compared to Young and Middle-Age Individuals. Frontiers in aging neuroscience, 7228. https://doi.org/10.3389/fnagi.2015.00228
Salini, Vincenzo, et al. "Platelet Rich Plasma Therapy in Non-insertional Achilles Tendinopathy: The Efficacy is Reduced in 60-years Old People Compared to Young and Middle-Age Individuals." Frontiers in aging neuroscience vol. 7 (2015): 228. doi: https://doi.org/10.3389/fnagi.2015.00228
Salini V, Vanni D, Pantalone A, Abate M. Platelet Rich Plasma Therapy in Non-insertional Achilles Tendinopathy: The Efficacy is Reduced in 60-years Old People Compared to Young and Middle-Age Individuals. Front Aging Neurosci. 2015 Dec 10;7:228. doi: 10.3389/fnagi.2015.00228. eCollection 2015. PMID: 26696880; PMCID: PMC4674567.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 428 entries